Physician profile
Stanley Kim
NPI 1306850433
$1,504.35
in general payments reported to CMS, 2019-2025
22 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $81.20 · 2021: $19.69 · 2022: $13.69 · 2023: $30.95 · 2024: $28.70 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.62 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $151.45 | 2019 | |
| Aerin Medical INC. | $148.40 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.99 | 2019 | |
| Novo Nordisk INC | $125.44 | 2019-2022 | |
| Allergan, INC. | $125.00 | 2019 | |
| Lilly USA, LLC | $124.06 | 2019-2020 | |
| Radius Health, INC. | $122.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $83.85 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $80.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $70.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $49.46 | 2019 | |
| Amgen INC. | $48.45 | 2019-2025 | Otezla, Repatha, Repatha |
| Mallinckrodt Enterprises LLC | $39.02 | 2019 | |
| Horizon Therapeutics Plc | $29.82 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.54 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $25.03 | 2025 | Pocket Eeg Device |
| Merck Sharp & Dohme LLC | $24.40 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.35 | 2023 | |
| Mallinckrodt Hospital Products INC. | $16.47 | 2020 | |
| Aimmune Therapeutics, INC. | $14.54 | 2024 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.